Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Interventions
DRUG:
Lorlatinib
Sponsor
Pfizer